1. AB0543 Remission using different composite disease indices in MTX-IR RA patients treated with abatacept or infliximab, +MTX. (23rd January 2014) Authors: Smolen, J.; Dougados, M.; Gaillez, C.; Poncet, C.; Le Bars, M.; Elegbe, A.; Schiff, M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0568 Efficacy of abatacept in patients with early (≤6 months) RA: Results from agree post-hoc analysis. (23rd January 2014) Authors: Westhovens, R.; Wollenhaupt, J.; Gomez Reino, J.J.; Grassi, W.; Le Bars, M.; Gaillez, C.; Poncet, C.; Elegbe, A.; Smolen, J.S. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0199 In patients with established RA, abatacept efficacy is independent of baseline annual radiographic progression rate. (23rd January 2014) Authors: Emery, P.; Westhovens, R.; Dougados, M.; Alten, R.; Gaillez, C.; Poncet, C.; Le Bars, M.; Elegbe, A.; Genant, H. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial. (23rd January 2014) Authors: Smolen, J. S.; Wollenhaupt, J.; Durez, P.; Gomez-Reino, J.; Grassi, W.; Le Bars, M.; Gaillez, C.; Poncet, C.; Westhovens, R. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study. (15th July 2016) Authors: Kirkham, B.; Mease, P.; McInnes, I.; Bhosekar, V.; Mpofu, S.; Gandhi, K.; Gaillez, C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP0113 No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies. (15th July 2016) Authors: Schreiber, S.; Sands, B.E.; Deodhar, A.; Baeten, D.; Huang, J.; Gandhi, K.; Karyekar, C.; Fox, T.; Gaillez, C. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients. (10th June 2014) Authors: Wulffraat, N.M.; Ruperto, N.; Brunner, H.I.; Oliveira, S.; Uziel, Y.; Nistala, K.; Cimaz, R.; Ferrandiz, M.A.; Flato, B.; Gamir, M.L.; Koné-Paut, I.; Gaillez, C.; Lheritier, K.; Abrams, K.; Martini, A.; Lovell, D.J. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients. (10th June 2014) Authors: Quartier, P.; Grom, A.; Ruperto, N.; Brunner, H.; Schikler, K.; Erguven, M.; Goffin, L.; Hofer, M.; Kallinich, T.; Marzan, K.; Gaillez, C.; Lheritier, K.; Abrams, K.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. SAT0109 Relationship Between Early Disease Activity Status and Structural and Functional Changes In Mtx-NaÏVe Patients with Early RA Treated with Abatacept Plus Mtx Versus Mtx Alone in the Agree Trial. (23rd January 2014) Authors: Smolen, J. S.; Yazici, Y.; Wollenhaupt, J.; Durez, P.; Gomez-Reino, J.; Grassi, W.; Le Bars, M.; Gaillez, C.; Poncet, C.; Westhovens, R. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3. (12th June 2018) Authors: Coates, L.C.; McGonagle, D.; Schett, G.; Mease, P.J.; Quebe-Fehling, E.; Asquith, D.L.; Rasouliyan, L.; Mpofu, S.; Gaillez, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗